JP4908210B2 - Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類 - Google Patents

Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類 Download PDF

Info

Publication number
JP4908210B2
JP4908210B2 JP2006521581A JP2006521581A JP4908210B2 JP 4908210 B2 JP4908210 B2 JP 4908210B2 JP 2006521581 A JP2006521581 A JP 2006521581A JP 2006521581 A JP2006521581 A JP 2006521581A JP 4908210 B2 JP4908210 B2 JP 4908210B2
Authority
JP
Japan
Prior art keywords
alkyl
ylmethylene
thiazolidine
oxo
dioxol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006521581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500171A (ja
JP2007500171A5 (https=
Inventor
リュックレ，トーマス
シャウ，ジェフリー
チャーチ，デニス
コビニ，ダビド
Original Assignee
メルク セローノ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク セローノ ソシエテ アノニム filed Critical メルク セローノ ソシエテ アノニム
Publication of JP2007500171A publication Critical patent/JP2007500171A/ja
Publication of JP2007500171A5 publication Critical patent/JP2007500171A5/ja
Application granted granted Critical
Publication of JP4908210B2 publication Critical patent/JP4908210B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2006521581A 2003-07-28 2004-07-27 Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類 Expired - Fee Related JP4908210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03102313.8 2003-07-28
EP03102313 2003-07-28
PCT/EP2004/051625 WO2005011686A1 (en) 2003-07-28 2004-07-27 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors

Publications (3)

Publication Number Publication Date
JP2007500171A JP2007500171A (ja) 2007-01-11
JP2007500171A5 JP2007500171A5 (https=) 2007-09-13
JP4908210B2 true JP4908210B2 (ja) 2012-04-04

Family

ID=34112474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521581A Expired - Fee Related JP4908210B2 (ja) 2003-07-28 2004-07-27 Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類

Country Status (9)

Country Link
US (1) US8106214B2 (https=)
EP (1) EP1648452B1 (https=)
JP (1) JP4908210B2 (https=)
CA (1) CA2531140C (https=)
DE (1) DE602004022170D1 (https=)
ES (1) ES2328146T3 (https=)
IL (1) IL173195A (https=)
NO (1) NO332434B1 (https=)
WO (1) WO2005011686A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718642A4 (en) * 2004-02-25 2010-11-24 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
MXPA06015028A (es) 2004-07-01 2007-02-08 Hoffmann La Roche Tiazolinas cinolinas no sustituidas.
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
US7241893B2 (en) 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
US7253285B2 (en) 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
CN101039939B (zh) * 2004-10-14 2010-07-07 霍夫曼-拉罗奇有限公司 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
CN101300047A (zh) * 2005-09-07 2008-11-05 雪兰诺实验室有限公司 Pi3k抑制剂用于子宫内膜异位症的治疗
US20080306057A1 (en) * 2005-10-11 2008-12-11 Laboratories Serono Sa P13K Inhibitors for the Treatment of Endometriosis
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
CL2007000995A1 (es) * 2006-04-11 2008-06-27 Smithkline Beecham Corp Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras.
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
PE20090288A1 (es) * 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
EP2255830A1 (en) 2008-03-03 2010-12-01 Takeda Pharmaceutical Company Limited Concomitant drug
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
MX2013000617A (es) * 2010-07-16 2013-06-13 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
CN102584809B (zh) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用
US9745323B2 (en) 2012-07-30 2017-08-29 Kyoto University Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
US10310802B2 (en) * 2014-03-26 2019-06-04 Unanimous A. I., Inc. System and method for moderating real-time closed-loop collaborative decisions on mobile devices
CN106588909B (zh) * 2017-01-06 2019-08-27 广东工业大学 一种喹啉类衍生物的制备及其在抗炎中的应用
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP4782564B2 (ja) 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
CN100579978C (zh) * 2002-11-22 2010-01-13 史密丝克莱恩比彻姆公司 化合物
CN101052640B (zh) 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途

Also Published As

Publication number Publication date
EP1648452A1 (en) 2006-04-26
JP2007500171A (ja) 2007-01-11
EP1648452B1 (en) 2009-07-22
NO20060573L (no) 2006-02-03
US20070021447A1 (en) 2007-01-25
AU2004260836A1 (en) 2005-02-10
US8106214B2 (en) 2012-01-31
IL173195A (en) 2013-04-30
CA2531140A1 (en) 2005-02-10
NO332434B1 (no) 2012-09-17
ES2328146T3 (es) 2009-11-10
IL173195A0 (en) 2006-06-11
DE602004022170D1 (de) 2009-09-03
WO2005011686A1 (en) 2005-02-10
CA2531140C (en) 2013-06-18

Similar Documents

Publication Publication Date Title
JP4908210B2 (ja) Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
US20040092561A1 (en) Azolidinone-vinyl fused -benzene derivatives
JP5226513B2 (ja) ピラジン誘導体及びその使用
CA2675884C (en) Quinoxaline compounds and use thereof
JP4782564B2 (ja) アゾリジノン−ビニル縮合−ベンゼン誘導体
US20090029997A1 (en) Thiazole Derivatives and Use Thereof
EP1567112A2 (en) Novel chemical compounds
JP5209311B2 (ja) ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用
CN101258149B (zh) 噻唑衍生物及其应用
AU2004260836B2 (en) 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as P13 kinase ihibitors
KR101131649B1 (ko) 아졸리디논-비닐 접합 벤젠 유도체
Gaillard et al. Ruckle et al.(43) Pub. Date: May 13, 2004
UA79793C2 (en) Azolidinone-vinyl fused-benzene derivatives
RS52006B (sr) Piridin metilen azolidinoni i njihova upotreba kao inhibitori fosfoinozitida
HK1123296B (en) Pyrazine derivatives and use as pi3k inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070725

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110722

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120112

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150120

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees